The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis

Abstract

Background: Allergic conjunctivitis (AC) is a multifactorial and common type of ocular surface disease that affects many people. The quality of life for AC patients can be significantly decreased caused by symptoms of ocular itching, swelling, redness, and tearing. Topical antihistaminics, mast cell stabilizers, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids have been widely used to treat AC. Many clinical trials have indicated that olopatadine hydrochloride eye drops can provide quick relief of symptoms and signs. The purpose of this review is to evaluate systematically the effectiveness of olopatadine hydrochloride eye drops for treating AC. Methods: A systematic review of all of the randomized controlled trials on the effectiveness and safety of olopatadine hydrochloride eye drops for AC will be conducted. We will search PubMed, Web of Science (WOS), EMBASE (OVID), the Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal database (VIP), Wanfang Database, and CBM, from the database inception date to October 31, 2019. There are no language or publication status restrictions. Registers of clinical trials, potential gray literature, reference lists of studies, and conference abstracts will also be searched. Two reviewers will independently read the articles, extract the data information, and assess the quality of the studies. Data will be synthesized by a heterogeneity test. The primary outcomes include the main symptom and sign scores before and after treatment, the eye redness index, the presence of eosinophils in the conjunctival scraping. Quality of life, the total treatment efficacy, and safety will be evaluated as the secondary outcomes. RevMan V.5.3 software will be used for the meta-analysis. Results: The study will provide an objective and normative systematic review to evaluate the effectiveness and safety of olopatadine hydrochloride eye drops for the treatment of AC. Conclusion: Our review will provide useful information to judge whether olopatadine hydrochloride eye drops is an effective intervention for patients with AC. Ethics and dissemination: It is not necessary to obtain ethical approval as participants are not involved patients. The protocol and results will be published in a peer-reviewed journal. The systematic review will also be disseminated electronically and in print to help guide health care practice and policy. Prospero registration number: PROSPERO CRD42019132232.

Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis

“…In a previous pharmacokinetic study, the concentrations of olopatadine were observed at the time points after single and multi-dose exposure in healthy subjects after 7d. Result showed that olopatadine was slowly absorbed in all participants and then rapidly eliminated from the body [20] . The common non-ocular adverse events associated with olopatadine include headache, nasal dryness, dysgeusia, and fatigue, which are known antihistamine effects [21][22] .…”

Green and sensitive detection of olopatadine in aqueous humor using a signal‐on fluorimetric approach: GREEnness assessment

“…It belongs to a group of drugs called antihistamines, which act by impairing the impacts of histamine, a biomolecule in the body that causes allergic symptoms [18,19]. This drug comes in the form of eye drops and is commonly prescribed to relieve symptoms such as itching, redness, and watering of the eyes caused by allergies like hay fever or allergic conjunctivitis [20][21][22]. Most of the detection approaches for OLP are chromatographic approaches [23][24][25][26][27][28][29][30][31][32][33].…”

MiR-146a upregulates FOXP3 and suppresses inflammation by targeting HIPK3/STAT3 in allergic conjunctivitis

“…However, these therapies are largely based on symptomatic relief. Besides, the duration of eye drops remaining active in the conjunctival sac is relatively short, and it is difficult to maintain their efficacy (10). When the hypersensitivity reaction is re-ignited, patient relapse can easily occur.…”